| pubmed-article:19057204 | pubmed:abstractText | Febrile neutropenia causes significant morbidity and mortality in patients receiving antineoplastic chemotherapy. Antibiotic prophylaxis reduces the incidence of fever during chemotherapy, but its routine use remains controversial for patients at low risk of neutropenic infection. This article reviews recent research to clarify the issue. | lld:pubmed |
